Fundraising Fox
SANUWAVE Health
NASDAQ: SNWVEden Prairie, US · Nevada corporation
Find your way into SANUWAVE Health
Sign up to see every warm intro you have to SANUWAVE Health
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SANUWAVE Health team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Sanuwave develops FDA-cleared wound care technology that delivers ultrasound through a saline mist to promote tissue healing. Its products serve clinicians and patients managing chronic and acute wounds.
Founders & leadership
PS
Peter SteganoExecutive
AW
Andrew WalkoExecutive
IC
Iulian CioantaExecutiveIulian Cioanta has over 25 years of experience in medical device and biotechnology development across urology, cardiology, orthopedics, and wound care, including roles as project manager, R&D director, and executive officer at companies ranging from startups to large corporations, and holds 121 issued patents. He has led product development, regulatory submissions, and clinical trials for FDA-regulated Class I, II, and III medical devices, and previously spent 8 years in academic research.
LE
Lisa E. SundstromExecutive
JC
Joseph ChiarelliExecutive
BJ
Barry J. JenkinsExecutive
MF
Morgan FrankChief Executive Officer, Chairman of the BoardMorgan Frank is Chief Executive Officer and Chairman of SANUWAVE Health, which develops FDA-cleared ultrasound-based wound care technology. He has experience as an investor and board member across small companies and ventures.
Board
KA
Kevin A. Richardson, IIBoard director
JF
John F. NemelkaBoard director
KA
Kevin A RichardsonBoard director
Reported raises · per SEC filings
Form D private placements$70.2M disclosed across 13 rounds · 2013–2024
▶$1.8MraisedJul 2024 · 9 investors · BiotechnologyRule 506(b)
▶$1.8MraisedJul 2024 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter SteganoExecutive Officer
- Andrew WalkoExecutive Officer
- A. Michael StolarskiDirector
- Morgan C. FrankDirector, Executive Officer
- Peter SorensenExecutive Officer
- Jeff BlizardDirector
- Kevin A. Richardson IIDirector
- Ian MillerDirector
- James TylerDirector
- Iulian CioantaExecutive Officer
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- First sale
- Jun 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4.6MraisedFeb 2024 · 19 investors · BiotechnologyRule 506(b)
▶$4.6MraisedFeb 2024 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Iulian CioantaExecutive Officer
- Toni RinowExecutive Officer
- Andrew WalkoExecutive Officer
- Kevin A. Richardson IIDirector, Executive Officer
- Morgan C. FrankDirector, Executive Officer
- Peter SteganoExecutive Officer
- A. Michael StolarskiDirector
- Ian MillerDirector
- Jeff BlizardDirector
- James TylerDirector
- Offering amount
- $4.6M
- Amount sold
- $4.6M
- First sale
- Jan 2024
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.9MraisedJan 2024 · 15 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJan 2024 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James TylerDirector
- Jeff BlizardDirector
- A. Michael StolarskiDirector
- Toni RinowExecutive Officer
- Peter SteganoExecutive Officer
- Kevin A. Richardson IIDirector, Executive Officer
- Ian MillerDirector
- Morgan C. FrankDirector, Executive Officer
- Andrew WalkoExecutive Officer
- Iulian CioantaExecutive Officer
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- Finders' fees
- $36.3K
- Placement agents
- Founding Asset Management Limited
- First sale
- Dec 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3MraisedAug 2023 · 17 investors · BiotechnologyRule 506(b)
▶$3MraisedAug 2023 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James TylerDirector
- Toni RinowExecutive Officer
- Morgan FrankDirector, Executive Officer
- Iulian CioantaExecutive Officer
- Ian MillerDirector
- Peter SteganoExecutive Officer
- Andrew WalkoExecutive Officer
- Jeff BlizardDirector
- A. Michael StolarskiDirector
- Kevin A Richardson IIDirector, Executive Officer
- Offering amount
- $3M
- Amount sold
- $3M
- Finders' fees
- $70.9K
- Placement agents
- Founding Asset Management Limited
- First sale
- Jul 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.2MraisedMay 2023 · 11 investors · BiotechnologyRule 506(b)
▶$1.2MraisedMay 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lisa SundstromExecutive Officer
- A. Michael StolarskiDirector
- Jeff BlizardDirector
- Toni RinowExecutive Officer
- Morgan FrankDirector
- Kevin Richardson IIDirector, Executive Officer
- James TylerDirector
- Iulian CioantaExecutive Officer
- Ian MillerDirector
- Peter SteganoExecutive Officer
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- May 2023
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$4MraisedDec 2022 · 32 investors · BiotechnologyRule 506(b)
▶$4MraisedDec 2022 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John SchlechtwegExecutive Officer
- Kevin Richardson IIExecutive Officer, Director
- Peter StegagnoExecutive Officer
- A. Michael StolarskiDirector
- Lisa SundstromExecutive Officer
- Jeff BlizardDirector
- Jim TylerDirector
- Iulian CioantaExecutive Officer
- Toni RinowExecutive Officer
- Ian MillerDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- Nov 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$16.2MraisedAug 2022 · 46 investors · BiotechnologyRule 506(b)
▶$16.2MraisedAug 2022 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ian MillerDirector
- Iulian CioantaExecutive Officer
- Toni RinowExecutive Officer
- John SchlechtwegExecutive Officer
- Kevin Richardson IIExecutive Officer, Director
- Peter StegagnoExecutive Officer
- Lisa SundstromExecutive Officer
- Jim TylerDirector
- A. Michael StolarskiDirector
- Jeff BlizardDirector
- Offering amount
- $16.2M
- Amount sold
- $16.2M
- Sales commissions
- $1.1M
- Placement agents
- The Benchmark Company, LLC
- First sale
- Aug 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$24.7MraisedAug 2020 · 46 investors · BiotechnologyRule 506(b)
▶$24.7MraisedAug 2020 · 46 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Iulian CioantaExecutive Officer
- Lisa A SundstrumExecutive Officer
- Maj-Britt KaltoftDirector
- Kevin RichardsonExecutive Officer
- Michael A StolarskiDirector
- Thomas PriceDirector
- John F NemelkaDirector
- Alan L RubinoDirector
- Peter StegagnoExecutive Officer
- Offering amount
- $24.7M
- Amount sold
- $24.7M
- Sales commissions
- $3.2M
- Placement agents
- LAKE STREET CAPITAL MARKETS, LLC, H.C.WAINWRIGHT & CO., LLC
- First sale
- Aug 2020
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does SANUWAVE Health do?
- Sanuwave develops FDA-cleared wound care technology that delivers ultrasound through a saline mist to promote tissue healing. Its products serve clinicians and patients managing chronic and acute wounds.
- How much funding has SANUWAVE Health raised?
- SANUWAVE Health has disclosed $70.2M raised across 13 rounds.
- Where is SANUWAVE Health headquartered?
- SANUWAVE Health is headquartered in Eden Prairie, US.